Article Text

Download PDFPDF
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Handling editor Josef S Smolen

  • Contributors AM and ZA contributed to the conception and design of the study. AM, MM, JR, MR, FC-A, BA-B, AB, CC, TC, MiD, MaD, RE, JF, NF, JH, MH, LJ, RL, TM, GR-C, JBP, MP, LP, PR, ER, DS, PS, CM-P, J-FV, J-SV, NB, NZ and BG were involved in the acquisition of data. AM, HY and ZA contributed to the analysis and interpretation of data. All authors contributed to drafting and/or revising the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Patients were informed that data collected in medical records might be used for research study in accordance with privacy rules.

  • Ethics approval This observational study was based on data extracted from medical records, in strict compliance with the French reference methodology MR‐004, established by the French National Commission on Informatics and Liberty (CNIL), in accordance with the French law, including the GPRD. This study was approved by the Research Ethics Committee of Sorbonne University (CER-2020-12).

  • Provenance and peer review Not commissioned; internally peer reviewed.